GILD
Gilead Sciences IncNASDAQHEALTHCAREDRUG MANUFACTURERS - GENERAL
Key Statistics
Market Cap
$171.45B
P/E Ratio
20.37
EPS
$6.78
Beta
0.37
52W High
$156.40
52W Low
$90.95
50-Day MA
$141.92
200-Day MA
$123.02
Dividend Yield
2.30%
Profit Margin
28.90%
Forward P/E
15.67
PEG Ratio
0.38
About Gilead Sciences Inc
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV, hepatitis B, hepatitis C, and influenza, including Harvoni and Sovaldi.
Fundamentals
| Revenue (TTM) | $29.44B |
| Gross Profit (TTM) | $23.21B |
| EBITDA | $14.58B |
| Operating Margin | 37.40% |
| Return on Equity | 40.70% |
| Return on Assets | 12.50% |
| Revenue/Share (TTM) | $23.67 |
| Book Value | $18.29 |
| Price-to-Book | 7.50 |
| Price-to-Sales (TTM) | 5.82 |
| EV/Revenue | 6.31 |
| EV/EBITDA | 13.67 |
| Quarterly Earnings Growth (YoY) | 23.40% |
| Quarterly Revenue Growth (YoY) | 4.70% |
| Shares Outstanding | $1.24B |
| Float | $1.24B |
| % Insiders | 0.13% |
| % Institutions | 92.61% |
Historical Volatility
HV 10-Day
17.84%
HV 20-Day
24.71%
HV 30-Day
29.01%
HV 60-Day
30.10%
HV Rank
58.7%
Volatility is currently contracting
Analyst Ratings
Consensus ($157.43 target)
5
Strong Buy17
Buy7
Hold1
Strong SellData last updated: 3/25/2026